P35052 (GPC1_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
April 3, 2013.
Version 108.
History...
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Glypican-1 Cleaved into the following chain: | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) [Reference proteome] | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 558 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Cell surface proteoglycan that bears heparan sulfate. Binds, via the heparan sulfate side chains, alpha-4 (V) collagen and participates in Schwann cell myelination By similarity. May act as a catalyst in increasing the rate of conversion of prion protein PRPN(C) to PRNP(Sc) via associating (via the heparan sulfate side chains) with both forms of PRPN, targeting them to lipid rafts and facilitating their interaction. Required for proper skeletal muscle differentiation by sequestering FGF2 in lipid rafts preventing its binding to receptors (FGFRs) and inhibiting the FGF-mediated signaling. Ref.10 Ref.12 |
| Subcellular location | Cell membrane; Lipid-anchor › GPI-anchor; Extracellular side. Endosome. Note: S-nitrosylated form recycled in endosomes. Localizes to CAV1-containing vesicles close to the cell surface. Cleavage of heparan sulfate side chains takes place mainly in late endosomes. Associates with both forms of PRNP in lipid rafts. Colocalizes with APP in perinuclear compartments and with CP in intracellular compartments. Associates with fibrillar APP Abeta peptides in lipid rafts in Alzheimer disease brains. Ref.1 Ref.5 Ref.7 Ref.9 Ref.10 Secreted glypican-1: Secreted › extracellular space Ref.5 Ref.7 Ref.9 Ref.10. |
| Post-translational modification | S-nitrosylated in a Cu2+-dependent manner. Nitric acid (NO) is released from the nitrosylated cysteines by ascorbate or by some other reducing agent, in a Cu2+ or Zn2+ dependent manner. This free nitric oxide is then capable of cleaving the heparan sulfate side chains. N- and O-glycosylated. N-glycosylation is mainly of the complex type containing sialic acid. O-glycosylated with heparan sulfate. The heparan sulfate chains can be cleaved either by the action of heparanase or, degraded by a daaminative process that uses nitric oxide (NO) released from the S-nitrosylated cysteines. This process is triggered by ascorbate, or by some other reducing agent, in a Cu2+- or Zn2+ dependent manner. Cu2+ ions are provided by ceruloproteins such as APP, PRNP or CP which associate with GCP1 in intracellular compartments or lipid rafts. Ref.1 Ref.4 Ref.7 Ref.8 Ref.9 Ref.11 Ref.12 Ref.13 This cell-associated glypican is further processed to give rise to a medium-released species. |
| Involvement in disease | Associates (via the heparan sulfate side chains) with fibrillar APP-beta amyloid peptides in primitive and classic amyloid plaques and may be involved in the deposition of these senile plaques in the Alzheimer disease (AD) brain. Ref.5 Ref.6 Misprocessing of GPC1 is found in fibroblasts of patients with Niemann-Pick Type C1 disease. This is due to the defective deaminative degradation of heparan sulfate chains. Ref.5 Ref.6 |
| Sequence similarities | Belongs to the glypican family. |
Ontologies
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 23 | 23 | Ref.1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Chain | 24 – 530 | 507 | Glypican-1 | PRO_0000012295 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Chain | 24 – ? | Secreted glypican-1 | PRO_0000333837 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Propeptide | 531 – 558 | 28 | Removed in mature form Probable | PRO_0000012296 | ||||||||||||||||||||||||||||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lipidation | 530 | 1 | GPI-anchor amidated serine Probable | |||||||||||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 79 | 1 | N-linked (GlcNAc...) Ref.11 Ref.13 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 116 | 1 | N-linked (GlcNAc...) Ref.1 Ref.11 Ref.13 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 486 | 1 | O-linked (Xyl...) (heparan sulfate) Probable | |||||||||||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 488 | 1 | O-linked (Xyl...) (heparan sulfate) Probable | |||||||||||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 490 | 1 | O-linked (Xyl...) (heparan sulfate) Probable | |||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 32 ↔ 68 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 62 ↔ 256 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 69 ↔ 259 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 191 ↔ 343 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 246 ↔ 279 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 268 ↔ 415 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 272 ↔ 401 | Ref.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 337 | 1 | A → D in a breast cancer sample; somatic mutation. Ref.14 | VAR_036044 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 500 | 1 | S → G. Ref.1 Ref.3 Corresponds to variant rs2228331 [ dbSNP | Ensembl ]. | VAR_033977 | ||||||||||||||||||||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 79 | 1 | N → Q: Protein yield reduced by half. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-116. Ref.11 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 116 | 1 | N → Q: No effect on protein yield. Protein yield reduced by 90%, abolishes N-glycosylation but no effect on secondary structure; when associated with Q-79. Ref.11 | |||||||||||||||||||||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 33 – 40 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 41 – 43 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 46 – 49 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 60 – 62 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 64 – 68 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 71 – 125 | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 127 – 129 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 132 – 152 | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 167 – 173 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 206 – 237 | 32 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 244 – 253 | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 256 – 259 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 269 – 284 | 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 287 – 299 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 300 – 304 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 310 – 315 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 374 – 388 | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 392 – 402 | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 418 – 422 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 431 – 433 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 434 – 436 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 440 – 442 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 451 – 471 | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts." David G., Lories V., Decock B., Marynen P., Cassiman J.-J., van den Berghe H. J. Cell Biol. 111:3165-3176(1990) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 24-53; 100-118 AND 298-317, GPI-ANCHOR, GLYCOSYLATION AT ASN-116, VARIANT GLY-500. Tissue: Lung fibroblast. |
| [2] | "Generation and annotation of the DNA sequences of human chromosomes 2 and 4." Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H. Wilson R.K.Nature 434:724-731(2005) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [3] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], VARIANT GLY-500. Tissue: Salivary gland. |
| [4] | "Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate." Mani K., Cheng F., Havsmark B., Jonsson M., Belting M., Fransson L.A. J. Biol. Chem. 278:38956-38965(2003) [PubMed] [Europe PMC] [Abstract] Cited for: COPPER-BINDING, NITROSYLATION, GLYCOSYLATION. |
| [5] | "Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease." Watanabe N., Araki W., Chui D.H., Makifuchi T., Ihara Y., Tabira T. FASEB J. 18:1013-1015(2004) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION, POSSIBLE ASSOCIATION WITH ALZHEIMER DISEASE. |
| [6] | "Defective nitric oxide-dependent, deaminative cleavage of glypican-1 heparan sulfate in Niemann-Pick C1 fibroblasts." Mani K., Cheng F., Fransson L.A. Glycobiology 16:711-718(2006) [PubMed] [Europe PMC] [Abstract] Cited for: S-NITROSYLATION, ASSOCIATION WITH NIEMANN-PICK TYPE C1 DISEASE. |
| [7] | "Constitutive and vitamin C-induced, NO-catalyzed release of heparan sulfate from recycling glypican-1 in late endosomes." Mani K., Cheng F., Fransson L.A. Glycobiology 16:1251-1261(2006) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION, NITROSYLATION, GLYCOSYLATION. |
| [8] | "Chemical and thermal unfolding of glypican-1: protective effect of heparan sulfate against heat-induced irreversible aggregation." Svensson G., Linse S., Mani K. Biochemistry 48:9994-10004(2009) [PubMed] [Europe PMC] [Abstract] Cited for: GLYCOSYLATION, ABSENCE OF GLYCOSYLATION AT SER-55. |
| [9] | "S-Nitrosylation of secreted recombinant human glypican-1." Svensson G., Mani K. Glycoconj. J. 26:1247-1257(2009) [PubMed] [Europe PMC] [Abstract] Cited for: NITROSYLATION, SUBCELLULAR LOCATION, GLYCOSYLATION. |
| [10] | "Glypican-1 mediates both prion protein lipid raft association and disease isoform formation." Taylor D.R., Whitehouse I.J., Hooper N.M. PLoS Pathog. 5:E1000666-E1000666(2009) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, SUBCELLULAR LOCATION. |
| [11] | "The structural role of N-linked glycans on human glypican-1." Svensson G., Hyrenius Wittsten A., Linse S., Mani K. Biochemistry 50:9377-9387(2011) [PubMed] [Europe PMC] [Abstract] Cited for: GLYCOSYLATION AT ASN-79 AND ASN-116, MUTAGENESIS OF ASN-79 AND ASN-116. |
| [12] | "Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation." Cheng F., Cappai R., Ciccotosto G.D., Svensson G., Multhaup G., Fransson L.A., Mani K. J. Biol. Chem. 286:27559-27572(2011) [PubMed] [Europe PMC] [Abstract] Cited for: NITROSYLATION, GLYCOSYLATION, FUNCTION. |
| [13] | "Crystal structure of N-glycosylated human glypican-1 core protein: Structure of two loops evolutionarily conserved in vertebrate glypican-1." Svensson G., Awad W., Hakansson M., Mani K., Logan D.T. J. Biol. Chem. 287:14040-14051(2012) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), DISULFIDE BONDS, LACK OF GLYCOSYLATION AT SER-55, GLYCOSYLATION AT ASN-79 AND ASN-116. |
| [14] | "The consensus coding sequences of human breast and colorectal cancers." Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V. Velculescu V.E.Science 314:268-274(2006) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT [LARGE SCALE ANALYSIS] ASP-337. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | X54232 mRNA. Translation: CAA38139.1. AC110619 Genomic DNA. Translation: AAY24160.1. BC051279 mRNA. Translation: AAH51279.1. | ||||||||||||||||||
| IPI | IPI00015688. | ||||||||||||||||||
| PIR | A36347. | ||||||||||||||||||
| RefSeq | NP_002072.2. NM_002081.2. | ||||||||||||||||||
| UniGene | Hs.328232. | ||||||||||||||||||
3D structure databases | |||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||
| ProteinModelPortal | P35052. | ||||||||||||||||||
| SMR | P35052. Positions 29-475. | ||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||
| STRING | 9606.ENSP00000264039. | ||||||||||||||||||
PTM databases | |||||||||||||||||||
| PhosphoSite | P35052. | ||||||||||||||||||
Polymorphism databases | |||||||||||||||||||
| DMDM | 292495012. | ||||||||||||||||||
Proteomic databases | |||||||||||||||||||
| PaxDb | P35052. | ||||||||||||||||||
| PRIDE | P35052. | ||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||
Genome annotation databases | |||||||||||||||||||
| Ensembl | ENST00000264039; ENSP00000264039; ENSG00000063660. | ||||||||||||||||||
| GeneID | 2817. | ||||||||||||||||||
| KEGG | hsa:2817. | ||||||||||||||||||
| UCSC | uc002vyw.4. human. | ||||||||||||||||||
Organism-specific databases | |||||||||||||||||||
| CTD | 2817. | ||||||||||||||||||
| GeneCards | GC02P241378. | ||||||||||||||||||
| H-InvDB | HIX0002996. | ||||||||||||||||||
| HGNC | HGNC:4449. GPC1. | ||||||||||||||||||
| HPA | HPA030571. | ||||||||||||||||||
| MIM | 600395. gene. | ||||||||||||||||||
| neXtProt | NX_P35052. | ||||||||||||||||||
| PharmGKB | PA28830. | ||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||
| eggNOG | NOG235988. | ||||||||||||||||||
| HOGENOM | HOG000253003. | ||||||||||||||||||
| HOVERGEN | HBG003464. | ||||||||||||||||||
| InParanoid | P35052. | ||||||||||||||||||
| KO | K08107. | ||||||||||||||||||
| OrthoDB | EOG4TXBRP. | ||||||||||||||||||
| PhylomeDB | P35052. | ||||||||||||||||||
Enzyme and pathway databases | |||||||||||||||||||
| Pathway_Interaction_DB | glypican_1pathway. Glypican 1 network. glypicanpathway. Glypican pathway. | ||||||||||||||||||
| Reactome | REACT_111045. Developmental Biology. REACT_111217. Metabolism. REACT_116125. Disease. | ||||||||||||||||||
Gene expression databases | |||||||||||||||||||
| ArrayExpress | P35052. | ||||||||||||||||||
| Bgee | P35052. | ||||||||||||||||||
| CleanEx | HS_GPC1. | ||||||||||||||||||
| Genevestigator | P35052. | ||||||||||||||||||
Family and domain databases | |||||||||||||||||||
| InterPro | IPR001863. Glypican. IPR015502. Glypican-1. IPR019803. Glypican_CS. [Graphical view] | ||||||||||||||||||
| PANTHER | PTHR10822. PTHR10822. 1 hit. PTHR10822:SF8. PTHR10822:SF8. 1 hit. | ||||||||||||||||||
| Pfam | PF01153. Glypican. 1 hit. [Graphical view] | ||||||||||||||||||
| PROSITE | PS01207. GLYPICAN. 1 hit. [Graphical view] | ||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||
Other | |||||||||||||||||||
| GenomeRNAi | 2817. | ||||||||||||||||||
| NextBio | 11103. | ||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||
Entry information
| Entry name | GPC1_HUMAN | ||||||||
| Accession | Primary (citable) accession number: P35052 Secondary accession number(s): Q53QM4 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 2 Human chromosome 2: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
